Traws Pharma (TRAW) Proxy Filing summary

Executive summary

• Special Meeting called to approve key proposals: conversion of Series C Preferred Stock, increase in authorized shares, reverse stock split, and potential adjournment to solicit more votes.

• Merger with Trawsfynydd Therapeutics completed April 1, 2024, with new equity issued and a $15 million financing round closed concurrently.

• Board recommends voting in favor of all proposals, citing improved financial resources and strategic positioning post-merger.

• H.C. Wainwright & Co. provided a fairness opinion supporting the exchange ratio for the merger.

Voting matters and shareholder proposals

• Proposal 1: Approve conversion of Series C Preferred Stock into Common Stock, enabling up to 124,727,687 new shares.

• Proposal 2: Amend Certificate of Incorporation to increase authorized Common Stock from 125M to 250M shares.

• Proposal 3: Approve a reverse stock split (1-for-15 to 1-for-25) to meet Nasdaq listing requirements.

• Proposal 4: Approve adjournment of the meeting if more time is needed to solicit votes.

• Board unanimously recommends voting FOR all proposals.

Board of directors and corporate governance

• Post-merger, Board consists of seven members: four from the legacy company, three from Trawsfynydd.

• CEO Werner Cautreels appointed as director; recent resignation of Dr. Fruchtman as President and CSO Oncology.

• Board retains authority to fill vacancies and issue preferred stock.